0001415889-22-008696.txt : 20220816 0001415889-22-008696.hdr.sgml : 20220816 20220816160429 ACCESSION NUMBER: 0001415889-22-008696 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220815 FILED AS OF DATE: 20220816 DATE AS OF CHANGE: 20220816 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Jacobs John C CENTRAL INDEX KEY: 0001820836 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 221170150 MAIL ADDRESS: STREET 1: 630 W. GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 4 1 form4-08162022_010808.xml X0306 4 2022-08-15 0001802665 Harmony Biosciences Holdings, Inc. HRMY 0001820836 Jacobs John C C/O HARMONY BIOSCIENCES HOLDINGS, INC. 630 W GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING PA 19462 true true false false PRESIDENT, CEO Common Stock 2022-08-15 4 M 0 40000 8.22 A 40000 D Common Stock 2022-08-15 4 S 0 39091 51.0542 D 909 D Common Stock 2022-08-15 4 S 0 909 51.7636 D 0 D Stock Option 8.22 2022-08-15 4 M 0 40000 0 D 2027-10-02 Common Stock 40000 114751 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.56 to $51.54. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.56 to $52.05. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option vests in five equal annual installments beginning on October 1, 2018. /s/ Christian Ulrich, Attorney-in-Fact 2022-08-16